Etzer Darout
Stock Analyst at Barclays
(4.55)
# 253
Out of 5,118 analysts
159
Total ratings
52.31%
Success rate
25.9%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Etzer Darout
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| XNCR Xencor | Maintains: Overweight | $23 → $26 | $15.17 | +71.39% | 8 | Dec 17, 2025 | |
| SRRK Scholar Rock Holding | Maintains: Overweight | $45 → $52 | $45.19 | +15.07% | 8 | Dec 17, 2025 | |
| PTGX Protagonist Therapeutics | Maintains: Overweight | $88 → $108 | $87.93 | +22.82% | 5 | Dec 17, 2025 | |
| JANX Janux Therapeutics | Maintains: Overweight | $48 → $29 | $14.07 | +106.11% | 3 | Dec 17, 2025 | |
| IOVA Iovance Biotherapeutics | Maintains: Overweight | $9 → $10 | $2.79 | +258.42% | 2 | Dec 17, 2025 | |
| CLDX Celldex Therapeutics | Maintains: Underweight | $21 → $24 | $26.03 | -7.80% | 3 | Dec 17, 2025 | |
| CCCC C4 Therapeutics | Maintains: Overweight | $10 → $5 | $2.03 | +146.31% | 6 | Dec 17, 2025 | |
| ARVN Arvinas | Maintains: Overweight | $16 → $18 | $11.90 | +51.26% | 7 | Dec 17, 2025 | |
| ANAB AnaptysBio | Maintains: Overweight | $70 → $55 | $50.91 | +8.03% | 3 | Dec 17, 2025 | |
| SMMT Summit Therapeutics | Upgrades: Equal-Weight | $16 → $18 | $17.78 | +1.24% | 3 | Dec 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $36 → $56 | $41.50 | +34.94% | 11 | Dec 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $70 → $119 | $80.35 | +48.10% | 4 | Dec 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $22 → $35 | $21.07 | +66.11% | 1 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $28 | $10.45 | +167.94% | 1 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $101 → $115 | $99.29 | +15.82% | 1 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $58 → $56 | $35.84 | +56.25% | 3 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $40 → $41 | $45.37 | -9.63% | 5 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $3.5 → $6 | $4.19 | +43.20% | 12 | Oct 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $61 | $4.33 | +1,308.78% | 1 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $48 | $30.90 | +55.34% | 1 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $125 | $65.57 | +90.64% | 1 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $16 | $7.45 | +114.77% | 1 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $142 | $140.40 | +1.14% | 1 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $112 → $97 | $90.00 | +7.78% | 8 | Sep 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $3 | $1.60 | +87.50% | 10 | Sep 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $13 | $4.55 | +185.71% | 4 | Sep 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $130 → $143 | $95.20 | +50.21% | 4 | Mar 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $22 → $3 | $3.20 | -6.25% | 3 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $35 | $19.36 | +80.79% | 1 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $63 | $1.76 | +3,479.55% | 1 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $28 → $27 | $2.36 | +1,044.07% | 7 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $132 → $134 | $101.76 | +31.68% | 6 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $46 → $48 | $32.52 | +47.60% | 3 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $118 → $120 | $139.20 | -13.79% | 3 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $7 → $6 | $1.00 | +501.50% | 7 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $80 → $82 | $92.52 | -11.37% | 4 | Apr 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $19 | $5.19 | +266.09% | 2 | Apr 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $170 | $398.82 | -57.37% | 2 | Feb 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $27 → $38 | $80.21 | -52.62% | 2 | Sep 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $52 | $3.01 | +1,627.57% | 1 | Mar 28, 2018 |
Xencor
Dec 17, 2025
Maintains: Overweight
Price Target: $23 → $26
Current: $15.17
Upside: +71.39%
Scholar Rock Holding
Dec 17, 2025
Maintains: Overweight
Price Target: $45 → $52
Current: $45.19
Upside: +15.07%
Protagonist Therapeutics
Dec 17, 2025
Maintains: Overweight
Price Target: $88 → $108
Current: $87.93
Upside: +22.82%
Janux Therapeutics
Dec 17, 2025
Maintains: Overweight
Price Target: $48 → $29
Current: $14.07
Upside: +106.11%
Iovance Biotherapeutics
Dec 17, 2025
Maintains: Overweight
Price Target: $9 → $10
Current: $2.79
Upside: +258.42%
Celldex Therapeutics
Dec 17, 2025
Maintains: Underweight
Price Target: $21 → $24
Current: $26.03
Upside: -7.80%
C4 Therapeutics
Dec 17, 2025
Maintains: Overweight
Price Target: $10 → $5
Current: $2.03
Upside: +146.31%
Arvinas
Dec 17, 2025
Maintains: Overweight
Price Target: $16 → $18
Current: $11.90
Upside: +51.26%
AnaptysBio
Dec 17, 2025
Maintains: Overweight
Price Target: $70 → $55
Current: $50.91
Upside: +8.03%
Summit Therapeutics
Dec 17, 2025
Upgrades: Equal-Weight
Price Target: $16 → $18
Current: $17.78
Upside: +1.24%
Dec 9, 2025
Maintains: Overweight
Price Target: $36 → $56
Current: $41.50
Upside: +34.94%
Dec 9, 2025
Maintains: Overweight
Price Target: $70 → $119
Current: $80.35
Upside: +48.10%
Nov 24, 2025
Maintains: Overweight
Price Target: $22 → $35
Current: $21.07
Upside: +66.11%
Nov 24, 2025
Maintains: Overweight
Price Target: $11 → $28
Current: $10.45
Upside: +167.94%
Nov 24, 2025
Maintains: Overweight
Price Target: $101 → $115
Current: $99.29
Upside: +15.82%
Nov 7, 2025
Maintains: Overweight
Price Target: $58 → $56
Current: $35.84
Upside: +56.25%
Nov 5, 2025
Maintains: Equal-Weight
Price Target: $40 → $41
Current: $45.37
Upside: -9.63%
Oct 21, 2025
Maintains: Overweight
Price Target: $3.5 → $6
Current: $4.19
Upside: +43.20%
Oct 13, 2025
Initiates: Overweight
Price Target: $61
Current: $4.33
Upside: +1,308.78%
Oct 13, 2025
Initiates: Overweight
Price Target: $48
Current: $30.90
Upside: +55.34%
Oct 13, 2025
Initiates: Overweight
Price Target: $125
Current: $65.57
Upside: +90.64%
Oct 13, 2025
Initiates: Overweight
Price Target: $16
Current: $7.45
Upside: +114.77%
Oct 13, 2025
Initiates: Overweight
Price Target: $142
Current: $140.40
Upside: +1.14%
Sep 30, 2025
Downgrades: Equal-Weight
Price Target: $112 → $97
Current: $90.00
Upside: +7.78%
Sep 17, 2025
Assumes: Overweight
Price Target: $3
Current: $1.60
Upside: +87.50%
Sep 2, 2025
Maintains: Buy
Price Target: $9 → $13
Current: $4.55
Upside: +185.71%
Mar 11, 2025
Maintains: Outperform
Price Target: $130 → $143
Current: $95.20
Upside: +50.21%
Feb 11, 2025
Downgrades: Market Perform
Price Target: $22 → $3
Current: $3.20
Upside: -6.25%
Dec 6, 2024
Initiates: Outperform
Price Target: $35
Current: $19.36
Upside: +80.79%
Dec 6, 2024
Initiates: Outperform
Price Target: $63
Current: $1.76
Upside: +3,479.55%
Nov 14, 2024
Maintains: Outperform
Price Target: $28 → $27
Current: $2.36
Upside: +1,044.07%
Nov 13, 2024
Maintains: Outperform
Price Target: $132 → $134
Current: $101.76
Upside: +31.68%
Nov 8, 2024
Reiterates: Outperform
Price Target: $46 → $48
Current: $32.52
Upside: +47.60%
Oct 30, 2024
Maintains: Market Perform
Price Target: $118 → $120
Current: $139.20
Upside: -13.79%
May 10, 2024
Maintains: Market Perform
Price Target: $7 → $6
Current: $1.00
Upside: +501.50%
Apr 26, 2024
Maintains: Outperform
Price Target: $80 → $82
Current: $92.52
Upside: -11.37%
Apr 25, 2023
Maintains: Outperform
Price Target: $20 → $19
Current: $5.19
Upside: +266.09%
Feb 3, 2022
Upgrades: Buy
Price Target: $170
Current: $398.82
Upside: -57.37%
Sep 9, 2020
Maintains: Buy
Price Target: $27 → $38
Current: $80.21
Upside: -52.62%
Mar 28, 2018
Maintains: Outperform
Price Target: $54 → $52
Current: $3.01
Upside: +1,627.57%